TNFSF15, Fc Chimera, Human
TNFSF15, Fc Chimera, Human

Immobilized Mouse DR3, His Tag at 2 μg/ml (100 μl/well) on the plate. Dose response curve for TNFSF15, Fc Chimera, Human, hFc Tag with the EC50 of 13.1ng/ml determined by ELISA.

TNFSF15, Fc Chimera, Human

Immobilized TNFSF15, Fc Chimera, Human, hFc Tag at 1 μg/ml (100 μl/well) on the plate. Dose response curve for Biotinylated Anti-TNFSF15 Antibody, hFc Tag with the EC50 of 15.5ng/ml determined by ELISA.

TNFSF15, Fc Chimera, Human

The purity of TNFSF15, Fc Chimera, Human is greater than 90% as determined by SEC-HPLC.

TNFSF15, Fc Chimera, Human

TNFSF15, Fc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

TNFSF15, Fc Chimera, Human

TNF superfamily member 15 (TNFSF15), a cytokine largely produced by vascular endothelial cells and a specific inhibitor of the proliferation of these same cells, can inhibit VEGF-induced vascular permeability in vitro and in vivo, and that death receptor 3 (DR3), a cell surface receptor of TNFSF15, mediates TNFSF15-induced dephosphorylation of VEGFR2.
Z05903
¥69,021.00

Ask us a question
Product Introduction
Species Human
Protein Construction
monomeric Fc TNFSF15 (Leu72-Leu251)_x000D_
Accession # O95150-1
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 44.87 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 48-60 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • TNFSF15, Fc Chimera, Human
    • TNFSF15, Fc Chimera, Human

    Immobilized Mouse DR3, His Tag at 2 μg/ml (100 μl/well) on the plate. Dose response curve for TNFSF15, Fc Chimera, Human, hFc Tag with the EC50 of 13.1ng/ml determined by ELISA.

  • TNFSF15, Fc Chimera, Human
    • TNFSF15, Fc Chimera, Human

    Immobilized TNFSF15, Fc Chimera, Human, hFc Tag at 1 μg/ml (100 μl/well) on the plate. Dose response curve for Biotinylated Anti-TNFSF15 Antibody, hFc Tag with the EC50 of 15.5ng/ml determined by ELISA.

  • TNFSF15, Fc Chimera, Human
    • TNFSF15, Fc Chimera, Human

    The purity of TNFSF15, Fc Chimera, Human is greater than 90% as determined by SEC-HPLC.

  • TNFSF15, Fc Chimera, Human
    • TNFSF15, Fc Chimera, Human

    TNFSF15, Fc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background TNF superfamily member 15 (TNFSF15), a cytokine largely produced by vascular endothelial cells and a specific inhibitor of the proliferation of these same cells, can inhibit VEGF-induced vascular permeability in vitro and in vivo, and that death receptor 3 (DR3), a cell surface receptor of TNFSF15, mediates TNFSF15-induced dephosphorylation of VEGFR2.
Synonyms TL1A; VEGI-251; TNFSF15; TL1; VEGI; VEGI192A

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.